Format

Send to

Choose Destination
Neurodegener Dis Manag. 2018 Apr;8(2):105-113. doi: 10.2217/nmt-2017-0056. Epub 2018 Apr 23.

Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.

Author information

1
Multiple Sclerosis Center, II Division of Neurology, Department of Clinical & Experimental Medicine, Second University of Naples, Naples, Italy.
2
Department of Neurology, University of Eastern Piedmont, Novara, Italy.
3
Neurological Clinic, Department of Experimental & Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
4
Neurology Service, Ospedale A. di Summa Perrino, Brindisi, Italy.
5
Dipartimento di Medicina, Clinica Neurologica, Università degli Studi di Perugia, Perugia, Italy.
6
Azienda Ospedaliera, Ospedale S. Corona, Pietra Ligure, Italy.

Abstract

AIM:

Complaints about Δ9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (Sativex®; GW Pharma Ltd, Salisbury, UK) in the management of multiple sclerosis spasticity include unpleasant taste and oral mucosal anomalies. This pilot study assessed the use of sugar-free chewing gum and/or a refrigerated bottle of THC:CBD oromucosal spray to mitigate these effects.

MATERIALS & METHODS:

Patients with multiple sclerosis spasticity (n = 52) at six sites in Italy who were receiving THC:CBD oromucosal spray and had associated oral mucosal effects were randomized into Group A (chewing gum; n = 15); Group B (cold bottle; n = 20); and Group C (cold bottle + chewing gum; n = 17).

RESULTS:

Taste perception in patients receiving chewing gum ± cold bottle intervention (Groups A and C combined) was significantly (p = 0.0001) improved from baseline to week 4 while maintaining spasticity control.

CONCLUSION:

Patient comfort, satisfaction and treatment adherence may benefit from these interventions.

KEYWORDS:

Sativex; THC:CBD; multiple sclerosis; oral cavity complaints; oromucosal spray; spasticity; taste perception

PMID:
29683408
DOI:
10.2217/nmt-2017-0056
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center